OntologiesCurators at RGD make annotations to genes, QTLs and strains using standardized vocabularies/ontologies. Your search returned annotations to the terms below.ChEBI: ChEBI Ontology
(-)-leucophyllone
(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol
(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride
(2R,3R,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)piperidin-3-yl hexopyranoside
(3S,3'S,4'R,6'S,8'R,8'aR)-5-[2-(1-hydroxycycloheptyl)ethynyl]-6'-[4-(2-hydroxyethoxy)phenyl]-1',2-dioxo-3',4'-diphenyl-8'-spiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]carboxamide
(ADMAdda5)microcystin-LHar
(ADMAdda5)microcystin-LR
(D-Asp3,ADMAdda5)microcystin-LR
(D-Ser1, ADMAdda)MC-LR
17alpha-ethynylestradiol
2-benzyl-3-hydroxypropanal
2-methyl-6-(phenylethynyl)pyridine
2-methyl-6-(phenylethynyl)pyridine hydrochloride
3-methyl-5-[(6-methyl-4-oxo-2,3-dihydropyran-2-yl)methyl]uran-2-carboxylic acid
4,4',4''-(4-propylpyrazole-1,3,5-triyl)trisphenol
4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline
4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate
4-fluoro-N-\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\}benzamide
4-fluoro-N-\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\}benzamide hydrochloride
[ADMAdda5,Dha7]MC-LR
[ADMAdda5,Mser7]MC-LR
[ADMAdda5]MC-(H4)YHar
[ADMAdda5]MC-(H4)YR
[ADMAdda5]MC-FR
[ADMAdda5]MC-HilHar
[ADMAdda5]MC-HilR
[ADMAdda5]MC-RR
[ADMAdda5]MC-YR
[Asp3, ADMAdda5, Dhb7] microcystin HtyR
[Asp3, ADMAdda5, Dhb7] microcystin LR
[Asp3, ADMAdda5, Dhb7] microcystin RR
[D-Asp3,ADMAdda5,Dha7]MC-HilR
[D-Asp3,ADMAdda5,Dha7]MC-LR
[D-Asp3,ADMAdda5]MC-(H4)YR
[D-Asp3,ADMAdda5]MC-HtyR
[D-Asp3,ADMAdda5]MC-LHar
[D-Asp3,ADMAdda5]MC-VR
[Gly1,D-Asp3,ADMAdda5,Dhb7]MC-LHar
[Gly1,D-Asp3,ADMAdda5,Dhb7]MC-LR
[Gly1,D-Asp3,ADMAdda5,Dhb7]MC-RHar
[Gly1,D-Asp3,ADMAdda5,Dhb7]MC-RR
[Gly1,D-Asp3,ADMAdda5]MC-LHar
[Gly1,D-Asp3,ADMAdda5]MC-LR
[Gly1,D-Asp3,ADMAdda5]MC-RHar
[Gly1,D-Asp3,ADMAdda5]MC-RR
\{4-[(4-Methylpiperazin-1-yl)methyl]phenyl\}methanol
ABBV-951
abiraterone
adamantane
aldoxorubicin
animal growth promotant
arformoterol
armodafinil
astromicin
auranofin
cefalotin
cefditoren
ceftibuten
ceftibuten dihydrate
cepharanthine
ceralasertib
cethromycin
CGP 78608
CGP 78608 hydrochloride
cilastatin
cilastatin sodium
colesevelam
colesevelam hydrochloride
crocetin
Darovasertib
Denifanstat
diagnostic agent
diagnostic imaging agent
difenoxin hydrochloride
dimercaprol
dirithromycin
enalapril maleate
enalaprilat dihydrate
eszopiclone
etodolac
Fenebrutinib
ferric ammonium citrate
formestane
GR 127935
GR 127935 hydrochloride
heroin
imetit
imetit dihydrobromide
iopromide
Leucokinin I
local anaesthetic
lomefloxacin hydrochloride
loxoprofen
loxoprofen sodium
loxoprofen sodium hydrate
methacetin-(methoxy-(13)C)
methoxsalen
N(omega),N(omega)-dimethyl-L-arginine
N-[(3R,4R,5S,6R)-5-[(2S,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-4,5-dihydroxyoxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-3,5-dihydroxy-4-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol
N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide
N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide
N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepinium-7,8-diol
nabumetone
nafadotride
nalidixic acid
nateglinide
nirmatrelvir
NTX-301
oxamniquine
Pac-1
Paxlovid
penciclovir
Pf-06840003
pirarubicin
porfimer sodium
potassium clavulanate
pro-agent
proacaricide
prodrug
profungicide
proglumetacin
proglumetacin dimaleate
proherbicide
proinsecticide
pronematicide
propesticide
prosafener
saracatinib
SB 224289
SB 224289 hydrochloride
Senicapoc
sertraline
sertraline hydrochloride
Simurosertib
Tas-116
telaglenastat
terbinafine
Tirabrutinib
trioxsalen
Trp-Ser-Arg
vanoxerine
vanoxerine dihydrochloride
xylose
zavegepant hydrochloride
CL: Cell Ontology
fallopian tube smooth muscle cell
CMO: Clinical Measurement
absolute change in adipocyte free fatty acid secretion
absolute change in adipocyte free fatty acid secretion per cell
absolute change in adipocyte free fatty acid secretion per unit volume
absolute change in adipocyte glucose uptake
blood AMG-8718 maximum concentration
blood asymmetric dimethylarginine level
calculated plasma asymmetric dimethylarginine level
dose of methacholine at which pulmonary conductance is half its pretreatment value
percentage of study population developing experimental diabetes mellitus during a period of time
percentage of study population displaying experimental diabetes mellitus at a point in time
plasma AMG-8718 maximum concentration
plasma arginine level to asymmetric dimethylarginine level ratio
plasma asymmetric dimethylarginine level
post-insult time to mammary tumor formation
post-insult time to onset of experimental diabetes mellitus
post-insult time to pituitary tumor formation
volume of distribution of nifedipine in the blood
EFO: Experimental Factor Ontology
(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride
17alpha-ethynylestradiol
2-methyl-6-(phenylethynyl)pyridine hydrochloride
4,4',4''-(4-propylpyrazole-1,3,5-triyl)trisphenol
4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate
4-fluoro-N-\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\}benzamide hydrochloride
a disintegrin and metalloproteinase with thrombospondin motifs 4
a disintegrin and metalloproteinase with thrombospondin motifs 4 (human)
a disintegrin and metalloproteinase with thrombospondin motifs 5
a disintegrin and metalloproteinase with thrombospondin motifs 5 (human)
abnormal glucose tolerance
acquired xanthinuria
acute pancreatitis
adamantinoma
adenosquamous breast carcinoma
adenosquamous colon carcinoma
ADHD symptom measurement
ADM (human)
ADM/CLMP protein level ratio in blood
ADM2 (human)
administrator
admixed ancestry
African American or Afro-Caribbean ancestry
agreeableness measurement
anosmin-1
anosmin-1 (human)
asymmetrical dimethylarginine measurement
attention function measurement
bone giant cell tumor
cardiotoxicity
cefalotin
CGP 78608 hydrochloride
Chane in Argentina (SGDP)
Colombian in Colombia (HGDP)
Colombian in Medellin, Colombia (1KGP)
Colorectal Adenosquamous Carcinoma
combined hepatocellular carcinoma and cholangiocarcinoma
compound based treatment
compound treatment design
conscientiousness measurement
COVID-19–associated multisystem inflammatory syndrome in adults
diagnostic agent
dimercaprol
dimethylarginine (SDMA + ADMA) measurement
dose
dose response design
Effort-induced polymorphic ventricular tachycardia
extraversion measurement
familial juvenile hyperuricemic nephropathy type 1
ferric ammonium citrate
formiminoglutamic aciduria
fractional excretion of lactulose to mannitol ratio
GR 127935 hydrochloride
Greater Middle Eastern (Middle Eastern or North African or Persian) ancestry
growth hormone insensitivity syndrome
Hereditary proximal myopathy with early respiratory failure
hospitalisation
imetit dihydrobromide
Impaired glucose tolerance
Intellectual disability
intoxication
investigator
Karitiana in Brazil (HGDP)
Karitiana in Brazil (SGDP)
Laron syndrome
Latin or Admixed American ancestry
leucine-induced hypoglycemia
level of protein ADM2 (human) in cerebrospinal fluid
level of protein ADM2 in blood serum
linguistic error measurement
lipoadenoma
loiasis
loneliness measurement
loxoprofen
Malignant Ovarian Mixed Epithelial Tumor
Maya in Mexico (HGDP)
Mayan in Mexico (SGDP)
metaplastic breast carcinoma
methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency
Mexican Ancestry in Los Angeles, California (1KGP)
milligram per day
Mini-International Neuropsychiatric Interview
Mixe in Mexico (SGDP)
Mixed Somatotroph-Lactotroph Pituitary Gland Adenoma
Mixtec in Mexico (SGDP)
myopathy, myofibrillar, 9, with early respiratory failure
N(omega),N(omega)-dimethyl-L-arginine
N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide
N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide
nafadotride
neuroleptic malignant syndrome
number of injections
openness measurement
oral motor function measurement
ovarian gonadoblastoma
Ovarian Mixed Epithelial Tumor
performance enhancing product use
personality trait measurement
Peruvian in Lima, Peru (1KGP)
Piapoco in Colombia (SGDP)
Pima in Mexico (HGDP)
Pima in Mexico (SGDP)
potassium deficiency
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
pro-adrenomedullin
pro-adrenomedullin (human)
pro-adrenomedullin proteolytic cleavage product
pro-adrenomedullin, signal peptide removed form
prodrug
protein ADM2
protein ADM2 (human)
Puerto Rican in Puerto Rico (1KGP)
Quechua in Peru (SGDP)
rectal adenosquamous carcinoma
response to BCG intravesical immunotherapy
response to combination chemotherapy
response to intravenous immunoglobulin therapy
response to vaccine
ropeginterferon alfa-2b
SB 224289 hydrochloride
sertraline hydrochloride
South Texas Assessment of Neurocognition
steroid-resistant nephrotic syndrome
subacute myelo-opticoneuropathy
substance withdrawal syndrome
Surui in Brazil (HGDP)
Surui in Brazil (SGDP)
syndromic multisystem autoimmune disease due to ITCH deficiency
syntactic complexity measurement
systemising measurement
terbinafine
Therapeutic Procedure
Thiamine-responsive megaloblastic anemia
total parenteral nutrition
tubulointerstitial kidney disease, autosomal dominant, 2
urocortin I
vancomycin trough measurement
vanoxerine dihydrochloride
vehicle role
vitamin B12-unresponsive methylmalonic acidemia type mut-
vitamin B12-unresponsive methylmalonic acidemia type mut0
xylose
Zapotec in Mexico (SGDP)
GO: Biological Process
amylin receptor 1 signaling pathway
amylin receptor 2 signaling pathway
xenobiotic metabolic process
GO: Cellular Component
amylin receptor complex 1
amylin receptor complex 2
GO: Molecular Function
dimethylargininase activity
HP: Human Phenotype
Abnormal oral glucose tolerance
Abnormal radioactive iodine uptake test result
Abnormal response to ACTH stimulation test
Abnormal response to corticotropin releasing hormone stimulation test
Abnormal response to gonadotropin-releasing hormone stimulation test
Abnormal response to insulin tolerance test
Abnormal TSH response to thyrotrophin-releasing hormone stimulation test
Ameliorated by colchicine
Ameliorated by ethosuximide
Ameliorated by vitamin D
Bloody bronchoalveolar lavage fluid
Decreased gonadotropin-stimulated testosterone-to-androstenedione ratio
Decreased growth hormone responses to growth hormone-releasing hormone challenge
Decreased post-bronchodilator forced expiratory flow 25-75%
Decreased post-bronchodilator forced expiratory volume in one second
Decreased post-bronchodilator forced vital capacity
Decreased pre-bronchodilator forced expiratory flow 25-75%
Decreased pre-bronchodilator forced vital capacity
Delayed scintigraphic gallbladder filling
Dependency on parenteral nutrition
Dexamethasone-suppressible primary hyperaldosteronism
Difficulty passing nasogastric tube
Effort-induced polymorphic ventricular tachycardia
Exacerbated by opiate medication
Exacerbated by phenytoin exposure
Exacerbated by sodium channel blocking agent exposure
Failure to increase oxygen saturation on hyperoxia test
Favorable response of weakness to acetylcholine esterase inhibitors
Fibrillary glomerular subepithelial deposits
Folate-responsive megaloblastic anemia
Folate-unresponsive megaloblastic anemia
Glucocortocoid-insensitive primary hyperaldosteronism
Heparin-induced thrombocytopenia
History of recent central venous catheter
History of recent iodated contrast medium administration
History of total parenteral nutrition dependence
Impaired folate absorption
Impaired glucose tolerance
Inappropriately low urine osmolality following challenge
Increased radioactive iodine uptake
Intellectual disability
Low urinary cyclic AMP response to PTH administration
Mesangial fibrillary deposits
Microcoria
Parkinsonism with favorable response to dopaminergic medication
Perihepatic enhancement
Positive hydrogen breath test
Positive lactose hydrogen breath test
Positive perchlorate discharge test
Positive regitine blocking test
Pyrimidine-responsive megaloblastic anemia
Reduced radioactive iodine uptake
Renal interstitial xanthogranulomatous inflammation
Thiamine-responsive megaloblastic anemia
Triggered by exposure to medication
Triggered by levothyroxin exposure
Unfavorable response of muscle weakness to acetylcholine esterase inhibitors
MI: Molecular Interactions
chemical footprinting
enzymatic footprinting
pharmacokinetics attribute name
MMO: Measurement Methods
contextual fear conditioning test
cued fear conditioning test
fear conditioning test
positron emission tomography (PET)
two way shuttlebox apparatus method
MP: Mammalian Phenotype
abnormal cocaine self-administration
abnormal extinction of cocaine self-administration
abnormal sensitization
abnormal sensitization to xenobiotic
decreased susceptibility to alcohol-induced hepatic steatosis
hyperactivity elicited by ethanol administration
increased susceptibility to alcohol-induced hepatic steatosis
pancreatic acinar-to-ductal metaplasia
NBO: Neuro Behavioral Ontology
alcohol withdrawal induced seizure
amphetamine overdose induced seizure
antidepressant overdose induced seizure
auditory kindling induced seizure
barbiturates withdrawal induced seizure
benzodiazepine withdrawal induced seizure
chemical kindling induced seizure
cocaine overdose induced seizure
drug induced seizure
drug withdrawal induced seizure
electrical kindling induced seizure
heroin withdrawal induced seizure
isoniazide overdose induced seizure
kindling induced seizure
penicillin overdose induced seizure
pilomotor reflex
theophylline overdose induced seizure
trauma induced seizure
OBA: Ontology of Biological Attributes
ADM/CLMP protein level ratio in blood
level of protein ADM2 in blood serum
PW: Pathway Ontology
adefovir drug pathway
anesthetic drug pathway
benzodiazepine drug pathway
docetaxel response pathway
dopa responsive dystonia pathway
doxorubicin response pathway
drug pathway
eprotirome drug pathway
erythromycin biosynthetic pathway
esomeprazole drug pathway
gemcitabine pathway
gemcitabine pharmacodynamics pathway
gemcitabine pharmacokinetics pathway
ifosfamide drug pathway
ifosfamide pharmacodynamics pathway
lansoprazole drug pathway
omeprazole drug pathway
pantoprazole drug pathway
procainamide response pathway
rabeprazole drug pathway
xenobiotic metabolic pathway
RDO: RGD Disease Ontology
adenosquamous breast carcinoma
AUTOINFLAMMATORY DISEASE, MULTISYSTEM, WITH IMMUNE DYSREGULATION, X-LINKED
autosomal dominant tubulointerstitial kidney disease 1
autosomal dominant tubulointerstitial kidney disease 2
Contrast-Induced Nephropathy
Drug-Induced Immune Thrombocytopenia
endocervical type cervical adenomyoma
endometrial type cervical adenomyoma
Experimental Colitis
Experimental Diabetes Mellitus
Fat Embolism
glucocorticoid-remediable aldosteronism
grade III lymphomatoid granulomatosis
Heparin-induced Thrombocytopenia
hereditary combined deficiency of vitamin K-dependent clotting factors
infantile onset multisystem autoimmune disease 1
infantile onset multisystem autoimmune disease 2
infantile onset multisystem autoimmune disease 3
inflammatory myofibroblastic tumor
lipoadenoma
Multisystem Autoimmune Disease with Facial Dysmorphism
neonatal lethal pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome
neuroleptic malignant syndrome
Positive-Pressure Respiration, Intrinsic
Potassium Deficiency
primary localized cutaneous amyloidosis 3
radiation-induced lung injury
scleritis
sebaceous breast carcinoma
Serum Sickness
Takotsubo Cardiomyopathy
RS: Rat Strains
HS/Rrrc
LS/Rrrc
SD-Admem1Soar
UBERON: Cross-Species Anatomy
anterodorsal nucleus of medial geniculate body
nucleus raphe magnus
nutrient foramen conduit
VT: Vertebrate Trait Ontology
type IIa muscle fiber quantity
XCO: Experimental Condition
17alpha-ethynylestradiol
amino acid
amoxicillin
Aprotinin
arthritis inducing chemical
arthritis-inducing agent
diagnostic agent
diagnostic imaging agent
experimental condition
floxuridine
forced feeding
Imwitor 742
Intralipid 20
manganese(II) chloride tetrahydrate
nateglinide
PEG-fusion protocol
physical manipulation
physical restraint
total parenteral nutrition
tumor promoter
vehicle control condition
PathwaysPathways with diagrams.doxorubicin response pathway |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



















